176 related articles for article (PubMed ID: 35341929)
41. Dual Chromatin and Cytoskeletal Remodeling by SETD2.
Park IY; Powell RT; Tripathi DN; Dere R; Ho TH; Blasius TL; Chiang YC; Davis IJ; Fahey CC; Hacker KE; Verhey KJ; Bedford MT; Jonasch E; Rathmell WK; Walker CL
Cell; 2016 Aug; 166(4):950-962. PubMed ID: 27518565
[TBL] [Abstract][Full Text] [Related]
42. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
Sankaran SM; Wilkinson AW; Elias JE; Gozani O
J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
[TBL] [Abstract][Full Text] [Related]
43. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
44. Methylation of histone H3 lysine 36 is required for normal development in Neurospora crassa.
Adhvaryu KK; Morris SA; Strahl BD; Selker EU
Eukaryot Cell; 2005 Aug; 4(8):1455-64. PubMed ID: 16087750
[TBL] [Abstract][Full Text] [Related]
45. Understanding histone H3 lysine 36 methylation and its deregulation in disease.
Li J; Ahn JH; Wang GG
Cell Mol Life Sci; 2019 Aug; 76(15):2899-2916. PubMed ID: 31147750
[TBL] [Abstract][Full Text] [Related]
46. Interplay between Histone and DNA Methylation Seen through Comparative Methylomes in Rare Mendelian Disorders.
Velasco G; Ulveling D; Rondeau S; Marzin P; Unoki M; Cormier-Daire V; Francastel C
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916664
[TBL] [Abstract][Full Text] [Related]
47. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
Lutsik P; Baude A; Mancarella D; Öz S; Kühn A; Toth R; Hey J; Toprak UH; Lim J; Nguyen VH; Jiang C; Mayakonda A; Hartmann M; Rosemann F; Breuer K; Vonficht D; Grünschläger F; Lee S; Schuhmacher MK; Kusevic D; Jauch A; Weichenhan D; Zustin J; Schlesner M; Haas S; Park JH; Park YJ; Oppermann U; Jeltsch A; Haller F; Fellenberg J; Lindroth AM; Plass C
Nat Commun; 2020 Oct; 11(1):5414. PubMed ID: 33110075
[TBL] [Abstract][Full Text] [Related]
48. Role of NSD1 as potential therapeutic target in tumor.
Yang C; Wang K; Liang Q; Tian TT; Zhong Z
Pharmacol Res; 2021 Nov; 173():105888. PubMed ID: 34536546
[TBL] [Abstract][Full Text] [Related]
49. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
50. Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.
Shipman GA; Padilla R; Horth C; Hu B; Bareke E; Vitorino FN; Gongora JM; Garcia BA; Lu C; Majewski J
bioRxiv; 2023 Oct; ():. PubMed ID: 37905045
[TBL] [Abstract][Full Text] [Related]
51. Histone 3 lysine 36 to methionine mutations stably interact with and sequester SDG8 in Arabidopsis thaliana.
Lin G; Zhou Y; Li M; Fang Y
Sci China Life Sci; 2018 Feb; 61(2):225-234. PubMed ID: 28975546
[TBL] [Abstract][Full Text] [Related]
52. Ash1 counteracts Polycomb repression independent of histone H3 lysine 36 methylation.
Dorafshan E; Kahn TG; Glotov A; Savitsky M; Walther M; Reuter G; Schwartz YB
EMBO Rep; 2019 Apr; 20(4):. PubMed ID: 30833342
[TBL] [Abstract][Full Text] [Related]
53. The NSD family of protein methyltransferases in human cancer.
Vougiouklakis T; Hamamoto R; Nakamura Y; Saloura V
Epigenomics; 2015 Aug; 7(5):863-74. PubMed ID: 25942451
[TBL] [Abstract][Full Text] [Related]
54. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
55. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].
Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722
[No Abstract] [Full Text] [Related]
56. Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Farhangdoost N; Horth C; Hu B; Bareke E; Chen X; Li Y; Coradin M; Garcia BA; Lu C; Majewski J
Cell Rep; 2021 Feb; 34(8):108769. PubMed ID: 33626351
[TBL] [Abstract][Full Text] [Related]
57. H3K36 methyltransferase NSD1 is essential for normal B1 and B2 cell development and germinal center formation.
Zhai S; Cao M; Zhou H; Zhu H; Xu T; Wang Y; Wang X; Cai Z
Front Immunol; 2022; 13():959021. PubMed ID: 36532012
[TBL] [Abstract][Full Text] [Related]
58. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase.
Fang J; Feng Q; Ketel CS; Wang H; Cao R; Xia L; Erdjument-Bromage H; Tempst P; Simon JA; Zhang Y
Curr Biol; 2002 Jul; 12(13):1086-99. PubMed ID: 12121615
[TBL] [Abstract][Full Text] [Related]
59. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
[TBL] [Abstract][Full Text] [Related]
60. Probe the function of histone lysine 36 methylation using histone H3 lysine 36 to methionine mutant transgene in mammalian cells.
Fang D; Gan H; Wang H; Zhou H; Zhang Z
Cell Cycle; 2017 Oct; 16(19):1781-1789. PubMed ID: 28129023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
